FDA panel backs Avastin for previously-treated glioblastoma
Roche and Genentech’s oncology blockbuster Avastin has received a recommendation from a US advisory panel for approval as a treatment of the most aggressive type of brain cancer.
Read MoreAuthor: Kevin Grogan
PMAs urged to cut funding from pharma down to 0%
A group of well-known researchers and doctors are calling on professional medical associations (PMAs) to reduce their reliance on funding from the pharmaceutical sector in order to preserve their integrity.
Read MoreSanofi touted as bidder for Solvay pharma ops; buys Kendrick
Belgium’s Solvay says it is looking at alternatives for its pharmaceuticals business and the latter’s future within the group.
Read MoreGSK completes Cervarix submission in the USA
The likelihood of GlaxoSmithKline’s Cervarix reaching the US market has been given a boost after the company said it has submitted final data from a key study of the cervical cancer vaccine to the Food and Drug Administration.
Read MoreLilly in CV pact with India’s Zydus, antipsychotic fails in Phase II
Eli Lilly has signed up another drug development partner in India, having inked a cardiovascular research pact with Zydus Cadila.
Read More- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
